BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Frantz C, Huscher D, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G, Siegert E, Lazzaroni MG, Carreira PE, Vettori S, Zanatta E, Ullman S, Czirjàk L, Kowal-Bielecka O, Distler O, Matucci-Cerinic M, Allanore Y; EUSTAR co-authors. Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. Autoimmun Rev 2020;19:102452. [PMID: 31838157 DOI: 10.1016/j.autrev.2019.102452] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Campochiaro C, Lazzaroni MG, Bruni C, Zanatta E, De Luca G, Matucci-Cerinic M. Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review. Ther Adv Musculoskelet Dis 2022;14:1759720X221116408. [PMID: 36051631 DOI: 10.1177/1759720X221116408] [Reference Citation Analysis]
2 Assassi S, Shao N, Yin Z, Volkmann ER, Zoz DF, Leonard TB. Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study. Medicine (Baltimore) 2022;101:e29993. [PMID: 35960051 DOI: 10.1097/MD.0000000000029993] [Reference Citation Analysis]
3 Lescoat A, Murphy SL, Chen YT, Vann N, Galdo FD, Cella D, Buch MH, Khanna D. Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study✰,✰✰,★,★★. Semin Arthritis Rheum 2021:S0049-0172(21)00199-2. [PMID: 34785028 DOI: 10.1016/j.semarthrit.2021.11.003] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Schneider U, Siegert E, Gläser S, Krüger K, Krause A; die Kommission Pharmakotherapie der DGRh. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis]. Z Rheumatol 2021;80:868-78. [PMID: 34545432 DOI: 10.1007/s00393-021-01088-y] [Reference Citation Analysis]
5 Selmi C. Autoimmunity in 2019. Clin Rev Allergy Immunol 2020;59:275-86. [PMID: 32729069 DOI: 10.1007/s12016-020-08808-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jaafar S, Lescoat A, Huang S, Gordon J, Hinchcliff M, Shah AA, Assassi S, Domsic R, Bernstein EJ, Steen V, Elliott S, Hant F, Castelino FV, Shanmugam VK, Correia C, Varga J, Nagaraja V, Roofeh D, Frech T, Khanna D. Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Res Ther 2021;23:170. [PMID: 34127049 DOI: 10.1186/s13075-021-02548-1] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
7 Lescoat A, Varga J, Matucci-Cerinic M, Khanna D. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. Expert Opin Investig Drugs 2021;30:635-52. [PMID: 33909517 DOI: 10.1080/13543784.2021.1923693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 David C, Chaigne B, Hollande C, Terris B, Cohen P, Dunogue B, Terrier B, Sogni P, Goulvestre C, Mouthon L. Primary biliary cholangitis and systemic sclerosis (Reynolds syndrome): A case-control study. Autoimmun Rev 2021;20:102842. [PMID: 33971338 DOI: 10.1016/j.autrev.2021.102842] [Reference Citation Analysis]
9 Sobanski V, Lescoat A, Launay D. Novel classifications for systemic sclerosis: challenging historical subsets to unlock new doors. Curr Opin Rheumatol 2020;32:463-71. [PMID: 32941248 DOI: 10.1097/BOR.0000000000000747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
10 Vonk MC, Walker UA, Volkmann ER, Kreuter M, Johnson SR, Allanore Y. Natural variability in the disease course of SSc-ILD: implications for treatment. Eur Respir Rev 2021;30:200340. [PMID: 33762426 DOI: 10.1183/16000617.0340-2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hysa E, Cutolo CA, Gotelli E, Paolino S, Cimmino MA, Pacini G, Pizzorni C, Sulli A, Smith V, Cutolo M. Ocular microvascular damage in autoimmune rheumatic diseases: The pathophysiological role of the immune system. Autoimmun Rev 2021;20:102796. [PMID: 33722750 DOI: 10.1016/j.autrev.2021.102796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lescoat A, Roofeh D, Townsend W, Hughes M, Sandler RD, Zimmermann F, Pauling JD, Buch MH, Khanna D. Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. BMJ Open 2021;11:e044765. [PMID: 33707273 DOI: 10.1136/bmjopen-2020-044765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hoffmann-Vold AM, Bendstrup E, Dimitroulas T, Hesselstrand R, Morais A, Peltomaa R, Smith V, Welling J, Vonk MC, Wuyts WA. Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews. Rheumatology (Oxford) 2021:keab154. [PMID: 33587103 DOI: 10.1093/rheumatology/keab154] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Calderon LM, Pope JE. Scleroderma epidemiology update. Curr Opin Rheumatol 2021;33:122-7. [PMID: 33481429 DOI: 10.1097/BOR.0000000000000785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Scherlinger M, Lutz J, Galli G, Richez C, Gottenberg JE, Sibilia J, Arnaud L, Blanco P, Schaeverbeke T, Chatelus E, Truchetet ME. Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatments. Semin Arthritis Rheum 2021;51:36-42. [PMID: 33360228 DOI: 10.1016/j.semarthrit.2020.10.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Conforti A, Di Cola I, Pavlych V, Ruscitti P, Berardicurti O, Ursini F, Giacomelli R, Cipriani P. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun Rev 2021;20:102735. [PMID: 33346115 DOI: 10.1016/j.autrev.2020.102735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
17 Giacomelli R, Afeltra A, Bartoloni E, Berardicurti O, Bombardieri M, Bortoluzzi A, Carubbi F, Caso F, Cervera R, Ciccia F, Cipriani P, Coloma-Bazán E, Conti F, Costa L, D'Angelo S, Distler O, Feist E, Foulquier N, Gabini M, Gerber V, Gerli R, Grembiale RD, Guggino G, Hoxha A, Iagnocco A, Jordan S, Kahaleh B, Lauper K, Liakouli V, Lubrano E, Margiotta D, Naty S, Navarini L, Perosa F, Perricone C, Perricone R, Prete M, Pers JO, Pitzalis C, Priori R, Rivellese F, Ruffatti A, Ruscitti P, Scarpa R, Shoenfeld Y, Triolo G, Tzioufas A. The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. Autoimmun Rev 2021;20:102738. [PMID: 33326854 DOI: 10.1016/j.autrev.2020.102738] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
18 Karakontaki FV, Panselinas ES, Polychronopoulos VS, Tzioufas AG. Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development. Autoimmun Rev 2021;20:102742. [PMID: 33333235 DOI: 10.1016/j.autrev.2020.102742] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
19 Benvenuti F, Zanatta E, Avouac J, Müller-ladner U, Cozzi F, Hoffmann-vold A, Gabrielli A, Distler O, Matucci-cerinic M, Allanore Y, Doria A. The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. Expert Review of Clinical Immunology 2020;16:1065-74. [DOI: 10.1080/1744666x.2021.1836962] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Lescoat A, Murphy SL, Roofeh D, Pauling JD, Hughes M, Sandler R, Zimmermann F, Wessel R, Townsend W, Chung L, Denton CP, Merkel PA, Steen V, Allanore Y, Del Galdo F, Godard D, Cella D, Farrington S, Buch MH, Khanna D. Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. J Scleroderma Relat Disord 2021;6:66-76. [PMID: 34316516 DOI: 10.1177/2397198320961967] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Valentini G, Pope JE. Undifferentiated connective tissue disease at risk for systemic sclerosis: Which patients might be labeled prescleroderma? Autoimmun Rev 2020;19:102659. [PMID: 32942034 DOI: 10.1016/j.autrev.2020.102659] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Vanaken L, Landini N, Lenaerts J, Claeys E, Lenaerts J, Wuyts WA, Verschakelen J, De Langhe E. Progressive lung fibrosis and mortality can occur in early systemic sclerosis patients without pulmonary abnormalities at baseline assessment. Clin Rheumatol 2020;39:3393-400. [DOI: 10.1007/s10067-020-05105-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ledoult E, Launay D, Béhal H, Mouthon L, Pugnet G, Lega JC, Agard C, Allanore Y, Jego P, Fauchais AL, Harlé JR, Berthier S, Aouba A, Mekinian A, Diot E, Truchetet ME, Boulon C, Duhamel A, Hachulla E, Sobanski V; French National Scleroderma Cohort Network. Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis. Arthritis Res Ther 2020;22:30. [PMID: 32070422 DOI: 10.1186/s13075-020-2113-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]